Chronic myeloid leukemia (CML)
- BCR-ABL tyrosine-kinase inhibitor is foundational
- Choose TKI by disease risk, mutation + comorbidity
- Monitor BCR-ABL molecular response serially
- Switch therapy for resistance/intolerance
- Deep sustained response may permit treatment-free remission
- Blast-phase disease requires intensified leukemia strategy
Use at a glance
- BCR-ABL tyrosine-kinase inhibitor is foundational
Treatment options
- Switch therapy for resistance/intolerance
Other treatment options
- Deep sustained response may permit treatment-free remission
- Blast-phase disease requires intensified leukemia strategy
Monitoring / follow-up
- Choose TKI by disease risk, mutation + comorbidity
- Monitor BCR-ABL molecular response serially
Self-check
- What is foundational in treatment of Chronic myeloid leukemia (CML)?
BCR-ABL tyrosine-kinase inhibitor.
- What is required when Blast-phase disease occurs in Chronic myeloid leukemia (CML)?
intensified.
Drugs used for this (2)
All clinical uses · Open the interactive console ↗
